Replies to post #241164 on Amarin Corp Plc (AMRN)

[KCSVEN]

They need to resolve last overhang in this generic suit and then continually beat sales estimates every quarter. That’s how they’ll get the SP to rise in GIA. Though I feel they have a strong position in court a little disappointed it got to court when the vast majority don’t. Should not be an overhang at this point. I get the need to win in court at some point but that point, to me, is not after all the recent success and years and years of waiting. Perhaps generics just would not settle and no choice but missed opportunity here, it would take years for another suit to work its way through and with multiple settlements odds of going to trial in future would have been small.

Just seems With Amarin everything is the hard way.

[Retiredceo]

Jas.....they lose control when sales ramp. There will be no stopping the stock price. Vascepa will become a household name. People will be scrambling to acquire it even if they are relatively healthy.

[Biobillionair]

How to get Amarin and Vascepa out of this Iron Grip in the market – without a BO – I would like to hear people ‘with insight in the market’ – make comments on – Thanks :)

Sales. Once sales ramp-up the stock will be difficult and pointless to control. Amarin will start buying other assets and further development of other indications. GILD NASH trial could start the build out into other indications.

BB

[couldbebetter]

jasbg, "Without a BO?" How about a new, dynamic, young, CEO?
No offense to JT, he has accomplished much, but to GIA he is not the
right guy. JT reminds me of Joe Biden, at times can be very compelling,
but not charismatic. By the way, all the other suggestions by those who
replied are on target. My belief is that Vascepa should become an add-
on drug for most any other cancer therapy or medication (such as Keytruda.)
Of course I have never heard anyone from AMRN discuss such a prospect.
Nor any stock analyst for that matter. (JT would likely claim he has to
focus on CVD which is a large enough market by itself for Vascepa.)
Given the amount of cash AMRN now has, would a trial for a new indication
be called for? For example, a trial for DES? Regardless, I still thing
Vascepa is worth far more in the hands of BP.